Newsfeeds Archive - Page 2 of 3

1 minute read

Biote Sees FY23 Revenue $190M-$200M Vs $195.36M Est.

August 10, 4:33 PM

2023 Financial Outlook "Biote continues to drive profitable growth as we strengthen our capabilities, broaden our suite of product offerings and focus on therapeutic wellness solutions. Due to temporary

BTMD

16 minute read

Earnings

Earnings Scheduled For August 10, 2023

By Benzinga Insights

August 10, 6:59 AM

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.

AACG

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Pre-Market Session

By Benzinga Insights

May 10, 9:06 AM

Gainers CTI BioPharma (NASDAQ:CTIC) stock rose 85.1% to $8.92 during Wednesday’s pre-market session. The company’s market cap stands…

ADXN

29 minute read

Earnings

Earnings Scheduled For May 9, 2023

By Benzinga Insights

May 9, 6:03 AM

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.

ABNB

4 minute read

Earnings

Earnings Scheduled For March 28, 2023

By Benzinga Insights

March 28, 6:38 AM

Companies Reporting Before The Bell • Futu Holdings (NASDAQ:FUTU) is expected to report quarterly earnings at $0.70 per share on revenue of $237.12 million.

AADI

1 minute read

Biote Q3 Sales $41.97M Beat $41.86M Estimate

By Benzinga Newsdesk

November 8, 5:27 PM

Biote (NASDAQ:BTMD) reported quarterly sales of $41.97 million which beat the analyst consensus estimate of $41.86 million by 0.26 percent. This is a 17.89 percent increase over sales of $35.60 million the same period

BTMD

21 minute read

Earnings

Earnings Scheduled For November 8, 2022

By Benzinga Insights

November 8, 5:32 AM

Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.

ABCL

6 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 27, 2022

By Benzinga Insights

September 27, 10:05 AM

Upgrades

ARCO

1 minute read

Truist Securities Initiates Coverage On Biote with Buy Rating, Announces Price Target of $10

By Benzinga Newsdesk

September 27, 7:17 AM

Truist Securities analyst Gregory Fraser initiates coverage on Biote (NASDAQ:BTMD) with a Buy rating and announces Price Target of $10.

BTMD

2 minute read

News

Biote Announces Strategic Partnership With IMAC Holdings Will Add Certain Biote Services To Its Network Of Outpatient Clinics That Deliver Orthopedic, Regenerative, And Advanced, Non-Surgical Medical Procedures; No Terms Disclosed

By Benzinga Newsdesk

September 7, 8:45 AM

Biote Method to be available in IMAC outpatient medical clinics biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a high growth, differentiated medical practice-building business within

BACK